A significant advance in Alzheimer’s disease research has been made by researchers at the Icahn School of Medicine at Mount Sinai. They have identified a new way that could potentially slow down or even stop disease progression. The study focuses on the role of reactive astrocytes and the plexin-B1 protein in Alzheimer’s pathophysiology, providing important insights into brain cell communication and paving the way for innovative treatment strategies.This important study, published in Nature Neuroscience (DOI 10.1038/s41593-024-01664-w) on May 27, focuses on the involvement of reactive astrocytes and the plexin-B1 protein in the development of Alzheimer’s disease. The research provides valuable information about how brain cells communicate and offers potential new approaches for treating the disease. The study highlights the potential of manipulating the plexin-B1 protein to improve the brain’s ability to clear amyloid plaques, which are a key feature of Alzheimer’s disease. It also emphasizes the significant role of reactive astrocytes, a type of brain cell that becomes activated in response to injury or disease.paraphrasing software. This process helps manage the spacing around amyloid plaques, which impacts how other brain cells can reach and clear these harmful deposits. Roland Friedel, PhD, an Associate Professor of Neuroscience and Neurosurgery at Icahn Mount Sinai, stated, “Our findings present an encouraging opportunity to develop new treatments by enhancing how cells interact with these harmful plaques.” The research involved analyzing complex data comparing healthy individuals to those with Alzheimer’s in order to comprehend the molecular and cellular basis of the disease. Hongyan Zou, PhD, a Professor of Neurosurgery, also contributed to the study.
Dr. Neuroscience, from Icahn Mount Sinai and one of the main authors of the study, emphasized the wider impact of their discoveries: “Our study creates new opportunities for Alzheimer’s research, stressing the significance of cellular interactions in the development of treatments for neurodegenerative diseases.”
One of the most notable accomplishments of the study is the validation of multiscale gene network models of Alzheimer’s disease. “This study not only confirms one of the most important predictions from our gene network models but also significantly advances our understanding of Alzheimer’s. It lays a solid foundation for developing novel therapeutics targeted at it.”Bin Zhang, PhD, the Willard T.C. Johnson Research Professor of Neurogenetics at Icahn Mount Sinai and one of the study’s lead authors, stated, “By demonstrating the critical role of plexin-B1 in Alzheimer’s disease, the research underscores the potential of targeted therapies to disrupt the disease’s progression and create highly predictive network models.” The research team emphasizes the need for further research to translate these discoveries into treatments for human patients, despite their findings marking a significant advance in the fight against Alzheimer’s. “Our ultimate goal is to develop treatments that can prevent or slow down AAlzheimer’s progression,” Dr. Zhang explained, highlighting the team’s dedication to further investigating the therapeutic potential of plexin-B1.
This research is backed by the NIH National Institute on Aging (NIA) grants U01AG046170 and RF1AG057440 and is a part of the NIA-led Accelerating Medicines Partnership — Alzheimer’s Disease (AMP-AD) Target Discovery and Preclinical Validation program. This public-private partnership aims to reduce the time between the identification of potential drug targets and the creation of new drugs for the treatment and prevention of Alzheimer’s disease.
Â
